Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose-escalation and Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SAR650984 (Isatuximab) in Patients With Relapsed/Refractory Multiple Myeloma

NCT02514668 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02514668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02514668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose-escalation and Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SAR650984 (Isatuximab) in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
September 1, 2015
Completion date
December 2, 2021
Enrollment
55 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma